ASCENDIS PHARMA, OPHTHALMOLOGY DIVISION A/S: Financial statements 2017
CVR: 32323502
Source: annual report 2017, Danish Business Authority
01/01/2017 – 31/12/2017
ASCENDIS PHARMA, OPHTHALMOLOGY DIVISION A/S (CVR 32323502) has filed annual accounts for 2017. In 2017, the company reported a gross profit of EUR 257,277 and a net result of EUR -479,755 compared with EUR 3,444,680 the year before. That is a decrease of 92.1% compared with the year before. Equity in the 2017 report amounted to EUR 13,822,655. The solvency ratio was 99.9%.
- Gross Profit
- EUR 257,277
- Profit/Loss
- EUR -479,755
- Equity
- EUR 13,822,655
- Total Assets
- EUR 13,830,042
- Employees
- 0
Development
| Year | Revenue | Gross Profit | Profit/Loss | Equity | Employees |
|---|---|---|---|---|---|
| 2017 | - | 257K EUR | -480K EUR | 13.8M EUR | 0 |
| 2016 | - | 3.2M EUR | 3.4M EUR | 14.3M EUR | - |
| 2015 | - | 5.4M EUR | 5.6M EUR | 10.9M EUR | - |
| 2014 | - | 5.5M EUR | 5.8M EUR | 5.3M EUR | - |
| 2013 | - | 18.5M | 16.3M | 19.1M | - |
Official annual report
Keep an eye on ASCENDIS PHARMA, OPHTHALMOLOGY DIVISION A/S
Get notified instantly about new financial statements, ownership changes, management changes and status changes.
Set up monitoringEvents in 2017
ASCENDIS PHARMA, OPHTHALMOLOGY DIVISION A/S has published its annual report for 2016. Gross profit came to DKK 3,244,713, and the net result was DKK 3,444,680.
About ASCENDIS PHARMA, OPHTHALMOLOGY DIVISION A/S
ASCENDIS PHARMA, OPHTHALMOLOGY DIVISION A/S is a Danish company of the type Aktieselskab based in Hellerup, founded in 2012. The company is registered under the industry Fremstilling af farmaceutiske præparater. The company was previously named ACP 30.06.2012 1 A/S. The management consists of Jan Møller Mikkelsen. The board consists of Michael Wolff Jensen (chair), Anni Lotte Kirstine Pedersen and Jan Møller Mikkelsen. The company is owned by ASCENDIS PHARMA A/S. According to the 2025 annual report, the company had an average of 0 employees. In 2025, the company reported a gross profit of EUR 5,567,000 and a net result of EUR -5,238,000 compared with EUR 5,001,000 the year before. Equity in the 2025 report amounted to EUR -38,639,000.
